Jupiter Biotech Company Raises $2 Million to Fund Parkinson's Disease Clinical Trial
A Jupiter-based biopharmaceutical company announced Wednesday it has raised $2 million to fund clinical trials for a potential Parkinson's disease treatment, marking another milestone for the local biotech firm.
Jupiter Neurosciences, Inc., which trades on NASDAQ under the ticker symbol JUNS, closed the registered direct offering with investors on May 21st. The company sold approximately 7.1 million shares of common stock to raise the capital.
"Yesterday's capital raise helps the Company prepare for key milestones anticipated in the next year," said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. "We were able to significantly reduce our debt, which improves our balance sheet."
The Jupiter company plans to use the funds primarily to advance its Phase 2a clinical trial for JOTROL, a proprietary formulation based on resveratrol - a compound found in red wine and grapes. The treatment is being tested for its potential to protect brain cells in Parkinson's disease patients.
The clinical trial, called RESET (RESvEraTrol in Parkinson's Disease), is a multi-center, randomized, double-blind study designed to evaluate whether JOTROL can help preserve motor function in people with Parkinson's. In laboratory studies, the treatment showed statistically significant neuroprotective effects, including improved motor performance and grip strength.
The U.S. Food and Drug Administration granted the company an Investigational New Drug (IND) approval in November 2025, allowing the clinical trial to proceed.
Beyond the Parkinson's program, Jupiter Neurosciences said the funding will also support its planned acquisition of U.S. rights to ALA-002, an MDMA-based treatment for mental health conditions. The company is positioning itself at the intersection of neuroscience and emerging psychedelic therapies.
"With a cleaner capital structure of the company and additional cash in hand, we believe that we are well positioned for future financing opportunities," Rosén added.
Jupiter Neurosciences also markets Nugevia, a consumer longevity supplement, while advancing its pipeline of treatments targeting central nervous system disorders and neuroinflammation.
The company's stock trades publicly on the NASDAQ exchange, making it one of the few publicly-traded biotech firms headquartered in Jupiter.
For more information about the clinical trial, visit ClinicalTrials.gov and search for study NCT07592767.